The EACR Conference on liquid biopsies will provide a comprehensive overview of liquid biopsies in cancer. It will cover what is already in clinical practice, what is on the horizon in cancer patient management and the latest techniques and applications for detecting solid tumours using liquid biopsies.
Liquid biopsies are demonstrating the potential to support early detection and screening of cancer; as a prognostic tool, to predict treatment efficacy or resistance, to evaluate treatment toxicity and to monitor minimal residual disease and anticipate disease relapse. The diversity and combination of cancer analytes in blood (including cell-free DNA, cfRNA, CTCs, extracellular vesicles and proteins) have the potential to boost liquid biopsy utility further.
